Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.)

Haematologica. 2019 Nov;104(11):e540. doi: 10.3324/haematol.2019.232835.

¹ University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf [email protected].
² Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne.
³ Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
⁴ University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf.

No abstract available

Publication types